Influenza viruses exist in many forms, with varying levels of pathogenicity. One well-known example is avian influenza, which ranges from low-pathogenic (LPAI) to highly pathogenic (HPAI) strains. Highly pathogenic strains are essential for understanding emerging threats and developing diagnostics, vaccines, and antivirals, but they come with significant challenges, including BSL-3 containment requirements, global shipping restrictions, and increased safety risks for scientists.

How Reverse Genetics Enables Safer Influenza Research

Reverse genetics revolutionized influenza research in the late 1990s. Today, scientists use plasmid-based systems to modify specific regions of a strain’s genetic code. For example, by modifying the HA cleavage site associated with high pathogenicity, scientists can create a recombinant virus strain that is genetically defined, reproducible, and safe to handle in a BSL-2 environment. This process retains the key antigens and biological properties needed for assays and vaccine development without the same biosafety hurdles.

Beyond improving safety, reverse genetics also enables more precise assay design and interpretation. In addition to studying highly pathogenic strains directly, recombinant influenza systems generated through reverse genetics are widely used in research and assay development. For example, H6Nx recombinant viruses are commonly utilized in neuraminidase inhibition (NAI) and ELLA assays to minimize hemagglutinin (HA)-specific antibody cross-reactivity, allowing assay signals to more accurately reflect neuraminidase-directed antibody responses. Reverse genetics systems also support post-market surveillance efforts and evaluation of how emerging viral mutations may impact assay performance, diagnostic accuracy, vaccine effectiveness, and antiviral susceptibility.

Why Converting HPAI to LPAI Matters

For diagnostic developers and research laboratories, access to authentic HPAI samples is often limited due to biosafety and regulatory constraints. Recombinant virus engineering enables the creation of LPAI analogs that behave like their highly pathogenic counterparts but can be handled under BSL-2 conditions. Although often discussed in the context of avian influenza, the ability to safely modify viral pathogenicity has broader implications for influenza research and development. Utilizing recombinant virus engineering offers several advantages:

• Faster, more accessible assay validation across influenza subtypes
• Simplified global distribution with fewer regulatory bottlenecks
• Safer workflows without compromising data quality
• Reduced project timelines and smoother compliance processes
• More reliable results across laboratories worldwide.

What to Look for in a Recombinant Virus Partner

When choosing a manufacturer for recombinant influenza viruses, consider:

• Scientific expertise in influenza reverse genetics.
• Quality control data, including sequence confirmation and sterility checks.
• Proven compliance with biosafety and international transport regulations.
• Customization options, including authentic or chimeric constructs, site-specific mutations, or tailored titers.
• Collaborative support to align constructs with assay or therapeutic objectives.

Partnering to Support Recombinant Influenza Research

Microbiologics specializes in recombinant influenza development using reverse genetics technology. The Global Virology Center supports HPAI to LPAI conversion, enabling access to engineered influenza viruses that are QC-validated, sequence-confirmed, and suitable for BSL-2 use. These recombinant viruses enable scientists to work safely and efficiently, supporting diagnostics, vaccine design, and antiviral discovery worldwide. Looking to apply recombinant virus engineering in your work? Explore how custom viral stock production can support your research and development goals.

About the Author

Varun Bansal, Ph.D.

Varun Bansal, Ph.D., is a Senior scientist at Microbiologics with over 10 years of experience in molecular biology and cell-based assay systems. He specializes in custom virus engineering, assay development, and supporting pharma, diagnostics, and research clients with custom projects. Outside the lab, he enjoys exploring San Diego’s beaches and spending time with family.